Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Heterogeneity of canonical prostate cancer markers across lesions in metastatic castration-resistant prostate cancer.
Anna Trigos, Anupama Pasam, Andrisha–Jade Inderjeeth, Lachlan D. Cain, Sirui Weng, Vinita Gupta, Beate Sable, Katherine Paweletz, Julie M. Bailis, Yangyi Zhang, Yuzhou Feng, A. Antón, Ben Tran, Catherine Mitchell, Shahneen Sandhu (2023). Heterogeneity of canonical prostate cancer markers across lesions in metastatic castration-resistant prostate cancer.. , 41(6_suppl), DOI: https://doi.org/10.1200/jco.2023.41.6_suppl.219.
Article165 days agoPRINCE: Phase I trial of <sup>177</sup>Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Lavinia Spain, Lisa G. Horvath, Megan Crumbaker, A. Antón, Roslyn Wallace, Anupama Pasam, Mathias Bressel, E. Cassidy, Patricia Banks, Nattakorn Dhiantravan, Timothy Akhurst, Aravind Ravi Kumar, Ramin Alipour, Mark Scalzo, Scott Williams, Rodney J. Hicks, Michael S. Hofman (2022). PRINCE: Phase I trial of <sup>177</sup>Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).. , 40(16_suppl), DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.5017.
Article165 days agoMolecular classification of hormone‐sensitive and castration‐resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens
Kobe Yuen, Ben Tran, A. Antón, Habib Hamidi, Anthony J. Costello, Niall M. Corcoran, Nathan Lawrentschuk, Natalie Rainey, Marie C. Semira, Peter Gibbs, Sanjeev Mariathasan, Shahneen Sandhu, Edward E. Kadel (2022). Molecular classification of hormone‐sensitive and castration‐resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. , 82(9), DOI: https://doi.org/10.1002/pros.24346.
Article165 days ago577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Lavinia Spain, Lisa G. Horvath, Megan Crumbaker, A. Antón, Roslyn Wallace, Anupama Pasam, Mathias Bressel, E. Cassidy, Patricia Banks, Aravind Ravi Kumar, Ramin Alipour, Timothy Akhurst, Grace Kong, Ian D. Davis, Scott Williams, Rodney J. Hicks, Michael S. Hofman (2021). 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). , 32, DOI: https://doi.org/10.1016/j.annonc.2021.08.1090.
Article165 days agoThe tumor immune microenvironment differs between metastatic castrate resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC).
Kobe Yuen, Ben Tran, Peter Gibbs, A. Antón, Sanjeev Mariathasan, Shahneen Sandhu, Edward E. Kadel (2019). The tumor immune microenvironment differs between metastatic castrate resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC).. , 37(7_suppl), DOI: https://doi.org/10.1200/jco.2019.37.7_suppl.251.
Article165 days ago